Korean journal of aerospace and environmental medicine (항공우주의학회지)

Aerospace Medical Association of Korea (한국항공우주의학협회)
권호 표지
DOI QR코드

DOI QR Code

COVID-19 Vaccination for Pilots and Air Traffic Controllers

항공종사자와 코로나바이러스감염증-19 백신 예방 접종

  • Received : 2021.03.12
  • Accepted : 2021.03.31
  • Published : 2021.04.30
⟨ Previous Next ⟩

Abstract

The coronavirus disease-19 (COVID-19) vaccine is expected to play an important role in stopping the pandemic. Studies show that COVID-19 vaccines are effective at keeping you from getting COVID-19. Getting a COVID-19 vaccine will also help keep you from getting seriously ill even if you do get COVID-19. Efforts to find an effective vaccine against severe acute respiratory syndrome coronavirus 2 have progressed unprecedentedly through active support from public research grants and private-public partnership programs. Clinical studies have been actively conducted, and some vaccines are being vaccinated with approval for urgent use. The WHO has approved and supplied the Pfizer-BioNTech COVID-19 vaccine and the Oxford-AstraZeneca COVID-19 vaccine. In Korea, the Oxford-AstraZeneca vaccine was approved for urgent use, and vaccination began on February 26, 2021. In this paper, the efficacy and side effects of each vaccines and the effect on pilots and air traffic controllers related to COVID-19 vaccination were investigated in terms of aviation medicine.

Keywords

References

  1. World Health Organization (WHO). Weekly epidemiological update on COVID-19 - 23 Mar 2021 [Internet]. Geneva: WHO; 2021 [cited 2021 Mar 30]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---23-march-2021.
  2. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020;382:1969-1973. https://doi.org/10.1056/NEJMp2005630
  3. Korea Disease Control and Prevention Agency (KDCA). Coronavirus disease-19 vaccine and vaccination [Internet]. Cheongju: KDCA; 2021 [cited 2021 Feb 11]. Available from: http://www.xn--19-9n4ip0xd1egzrilds0a816b.kr.
  4. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 2021;397:72-74. https://doi.org/10.1016/S0140-6736(20)32623-4
  5. World Health Organization (WHO). Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca: interim guidance [Internet]. Geneva: WHO; 2021 [cited 2021 Feb 16]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1.
  6. European Medicines Agency (EMA). COVID-19 vaccine AstraZeneca: product information as approved by the CHMP on 29 January 2021, pending endorsement by the European Commission [Internet]. Amsterdam: EMA; 2021 [cited 2021 Feb 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf.
  7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615. https://doi.org/10.1056/NEJMoa2034577
  8. Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ 2020;371:m4471. https://doi.org/10.1136/bmj.m4471
  9. Foley KE. Everything we know about Johnson & Johnson's single-dose Covid-19 vaccine [Internet]. New York: Quartz; 2021 [cited 2021 Feb 15]. Available from: https://qz.com/1966390/what-we-know-about-johnson-johnsons-covid-19-vaccine/.
  10. Centers for Disease Control and Prevention (CDC). Key things to know about COVID-19 vaccines [Internet]. Atlanta: CDC; 2021 [cited 2021 Feb 26]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/keythingstoknow.html.
  11. Shimabukuro T. COVID-19 vaccine safety update [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2021 [cited 2021 Apr 2]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/06-COVID-Shimabukuro.pdf.
  12. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016;137:868-878. https://doi.org/10.1016/j.jaci.2015.07.048
  13. Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting [Internet]. London: Medicines & Healthcare products Regulatory Agency; 2021 [updated 2021 Apr 1; cited 2021 Apr 2]. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting.
  14. Remmel A. COVID vaccines and safety: what the research says. Nature 2021;590:538-540. https://doi.org/10.1038/d41586-021-00290-x
  15. Ministry of Land, Infrastructure and Transport. Manual for civil aviation medical examiners. Sejong: Ministry of Land, Infrastructure and Transport; 2013. pp. 188.
  16. Federal Aviation Administration (FAA). Novel coronavirus (COVID-19) update [Internet]. Washington, D.C.: FAA; 2021 [cited 2021 Mar 5]. Available from: https://www.faa.gov/news/updates/?newsId=94991.
  17. Medicines & Healthcare products Regulatory Agency. Information for UK recipients on COVID 19 vaccine AstraZeneca [Internet]. London: Medicines & Healthcare products Regulatory Agency; 2021 [cited 2021 Mar 5]. Available from: https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-uk-recipients-on-covid-19-vaccine-astrazeneca.
  18. European Union Aviation Safety Agency (EASA). Guidelines for aero-medical centres and aeromedical examiners regarding the examination and assessment of applicants. Guidelines in relation to the COVID-19 pandemic [Internet]. Koln: EASA; 2021 [cited 2021 Feb 26]. Available from: https://www.easa.europa.eu/sites/default/files/dfu/guidelines_for_aemcs_and_ames_regarding_the_examination_and_assessment_of_applicants.pdf.